$KRYS News

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses Forecasts

Krystal Biotech (NASDAQ:KRYS) Slips After Q2 Revenue Miss Despite EPS Beat

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Krystal Biotech (KRYS) Could Be 40% Overvalued As KB801 News Tests Its Price

Krystal Biotech (KRYS) Is Up 7.9% After S&P 400 Move And New KB801 Patent Filing Update

Krystal Biotech: International Expansion And A Vibrant Pipeline

Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due Course

Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup

B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $396

The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream

TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403

HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $361

Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?

Is the Options Market Predicting a Spike in Krystal Biotech Stock?